Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a biotechnology leader focused on developing gene therapies for rare neuromuscular and cardiac disorders, including Duchenne muscular dystrophy. This news hub provides investors and researchers with timely updates on the company's progress in advancing precision genetic medicines.
Access comprehensive coverage of SLDB's press releases, clinical trial milestones, financial disclosures, and strategic partnerships. Our curated news collection simplifies tracking critical developments in gene therapy innovation and regulatory advancements.
Key updates include announcements related to therapeutic pipelines, scientific collaborations, and market-moving events. Bookmark this page for streamlined access to verified information directly impacting SLDB's research trajectory and industry position.
Solid Biosciences (NASDAQ: SLDB) provided updates on its neuromuscular and cardiac development pipeline. The company has dosed four patients in the INSPIRE DUCHENNE trial for SGT-003, with initial three-patient data expected in Q1 2025. The FDA cleared an IND for SGT-212, a dual-route administration gene therapy for Friedreich's ataxia, with first-in-human trials planned for 2H 2025.
The company plans to submit an IND for SGT-501 to treat CPVT in 1H 2025. Additionally, Solid is advancing SGT-601 for TNNT2 Thin Filament Cardiomyopathy with IND submission planned for 2H 2026. The company has also collaborated with Mayo Clinic for developing therapies for cardiac conditions.
Solid enters 2025 with approximately $148.9 million in cash and investments, expected to fund key priorities into 2026.
Solid Biosciences (SLDB), a precision genetic medicines developer focusing on neuromuscular and cardiac diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bo Cumbo, President and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
The presentation will be accessible through a live webcast on the Company's website's Investors section under the Events page. A replay of the webcast will remain available for 30 days following the event. Institutional investors seeking meetings with management during the conference are advised to contact their J.P. Morgan representatives.
Solid Biosciences (NASDAQ: SLDB) has received FDA IND clearance for SGT-212, a pioneering dual-route gene therapy designed to treat Friedreich's ataxia (FA). This therapy is unique as it's the only candidate delivering full-length frataxin protein through both systemic intravenous infusion and direct intradentate nuclei infusion into the cerebellum.
The therapy aims to address both neurologic and cardiac manifestations of FA, targeting the insufficient levels of frataxin protein that cause this degenerative disease. Preclinical studies have shown safe transduction and frataxin expression in target tissues, demonstrating significant restoration of neurologic function and reversal of cardiac implications in mice.
The company plans to initiate a Phase 1b clinical trial in the second half of 2025. This first-in-human, open-label, dose-finding study will enroll both non-ambulatory and ambulatory adult FA patients across up to three cohorts, with participants being followed for five years after receiving SGT-212.
Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced on January 6, 2025, the grant of 11,847 restricted stock units (RSUs) to a newly hired employee.
The RSUs will vest in four equal installments on each one-year anniversary of the grant date, provided the employee continues to serve with the company through each vesting date. This grant was made under the company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has been added to the Nasdaq Biotechnology Index® (NBI) effective December 23, 2024. The NBI tracks performance of biotechnology and pharmaceutical securities listed on Nasdaq, using a modified capitalization-weighted methodology. Companies must meet specific eligibility criteria including minimum market capitalization, daily trading volume, and public company seasoning requirements. Index constituents are selected annually in December.
Solid Biosciences (SLDB) has announced a strategic collaboration with Mayo Clinic to advance AAV gene therapy development for cardiac diseases. The partnership grants Solid exclusive worldwide licenses to Mayo Clinic's Suppression-Replacement gene therapy platform and six cardiac gene therapy programs developed by their Windland Smith Rice Sudden Death Genomics Lab.
Under the agreement, Mayo Clinic will conduct research and development up to IND-enabling studies, after which Solid will have options for continued development and commercialization. The collaboration will utilize Solid's next-generation AAV capsids, including AAV-SLB101, and advanced manufacturing capabilities to target genetic heart diseases. The company expects to submit an IND for CPVT in the first half of 2025.
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has granted 11,847 restricted stock units (RSUs) to a new employee. The RSUs will vest in four equal annual installments over four years, contingent upon continued employment. The grant was made under the Company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, announces participation in two major healthcare conferences. At Citi's 2024 Global Healthcare Conference in Miami, President and CEO Bo Cumbo will join a panel on Neuromuscular Disorders on December 4, 2024, at 1:00 p.m. ET. The following day at the Piper Sandler 36th Annual Healthcare Conference in New York, Cumbo and Chief Medical Officer Gabriel Brooks will participate in a fireside chat at 9:30 a.m. ET. Both events will be webcast live and available for replay on the company's website for 30 days.
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's President and CEO, Bo Combo, along with Chief Medical Officer Gabriel Brooks, M.D., will deliver a presentation on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
The presentation will be accessible via live webcast on the company's website's Investors section under Events, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.
Solid Biosciences (SLDB) reported Q3 2024 financial results and business updates. The company completed dosing for the first three patients in the INSPIRE DUCHENNE trial, with SGT-003 showing good tolerability and no serious adverse events. Cash position stands at $171.1 million, providing runway into 2026. Q3 net loss increased to $32.7 million ($0.79 per share) from $21.0 million year-over-year. R&D expenses rose to $27.3 million from $16.7 million, while G&A expenses increased to $7.9 million from $6.4 million. The company expanded its study protocol and plans to present initial three-patient data in Q1 2025.
